跳至主要内容
临床试验/NCT05525117
NCT05525117撤回不适用

Evaluating the Effectiveness of an Online Self-management Intervention for Type 2 Diabetes Mellitus (Covivio): Randomized Controlled Trial

Gaia AG2 个研究点 分布在 1 个国家开始时间: 2023年7月4日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
Gaia AG
试验地点
2
主要终点
HbA1c

研究概览

简要总结

This trial was designed to evaluate the effectiveness of the dialogue-based online intervention covivio, which was designed to improve diabetes self-management in patients with type 2 diabetes.

The study aims to test the hypothesis that covivio has a greater positive impact on glycemic control than treatment as usual. Patients with type 2 diabetes mellitus will be randomized and allocated to either an intervention group, receiving covivio in addition to treatment as usual, or a control group, which receives only treatment as usual. The primary endpoint is the HbA1c value six month after baseline.

详细描述

The aim of this clinical trial is to investigate the effectiveness of the self-guided digital therapeutic covivio in 268 patients with type 2 diabetes mellitus (T2DM). Patients will be randomized and allocated in a 1:1 ratio to either an intervention group, in which they will receive access to covivio in addition to treatment as usual (TAU, n = 134), or to a control group, in which they will receive only TAU (n = 134).

The primary endpoint of this trial will be the between-groups difference of the HbA1c in the intervention and control group at six months adjusted for the baseline HbA1c. In order to show the course of change over time, two timepoints for assessment of effects are planned at four (T1) and six months (T2) after the baseline assessment (T0). The primary endpoint will be the HbA1c at six months post-allocation. Secondary endpoints will be depression, diabetes self-management (DSM), BMI, and quality of life. Figure 1 (section 6.1) summarizes the design of the clinical trial.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • diagnosis of T2DM (submission of a medical certificate attesting to the presence of at least one of the following ICD-10-GM diagnoses of T2DM: E11.20, E11.30, E11.40, E11.50, E11.60, E11.72, E11.74, E11.80, E11.90)
  • HbA1c value ≥ 7.0% (53 mmol/mol)
  • BMI ≥ 23 kg/m2
  • Consent to participate
  • Sufficient knowledge of the German language

排除标准

  • diagnosis of type 1 diabetes mellitus (T1DM)
  • change in medication, frequency of use or dosage (planned within 4 weeks before T0 or during the study period)

结局指标

主要结局

HbA1c

时间窗: 6 months

The primary objective of this study is to determine whether the online intervention covivio will reduce HbA1c values in the intervention group compared to the control group.

次要结局

  • Diabetes Self-management(6 months)
  • Depressive symptoms(6 months)
  • Body Mass Index(6 months)
  • Health-Related Quality of Life(6 months)
  • Proportion of patients achieving a reduction in HbA1c(6 months)

研究者

发起方
Gaia AG
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验